First-in-class anti-CD200R1 antibody 23ME00610 in patients with advanced solid malignancies: Phase 1 results

Authors
Category Primary study
JournalCancer Research
Year 2023
This article has no abstract
Epistemonikos ID: 93907b408c00f221a7cab2ae682c81cd16339f5b
First added on: Feb 16, 2025